Accretion Nutraveda IPO Details
Accretion Nutraveda
Offer Price₹129 Lot Size1,000 Listing Price ₹191 (48.06% ▲) Subscription1.83x Offer Time28 jan to 30 jan
Listed
Check Allotment Status Accretion Nutraveda IPO Deatils : GMP, Subscription, Date
- 📄 IPO Details
- 📊 IPO Subscribe
- 📅 Important Date
- 📈 Day Wise Gmp
- 🧮 Day Wise Subscribe
- 📦 Ipo Lot Size
- 🏷️ Ipo Reservation
- 🏢 About Company
- 🎯 Objective of Ipo
- 🚀 Financial Report
Ipo Details
| Field | Details |
|---|
| IPO Date | 28 to 30 Jan, 2026 |
| Listing Date | Wed, Feb 4, 2026 |
| Face Value | ₹10 per share |
| Price Band | ₹122 – ₹129 |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh Capital |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Total Issue Size | 19,20,000 shares (₹25 Cr) |
| Reserved for Market Maker | 96,000 shares (₹1 Cr) – Sunflower Broking Pvt. Ltd. |
| Net Offered to Public | 18,24,000 shares (₹24 Cr) |
| Share Holding Pre Issue | 53,20,000 shares |
| Share Holding Post Issue | 72,40,000 shares |
Subscription
| Anchor | 1.00x |
| QIB | 1.01x |
| NII | 2.08x |
| bNII | 1.95x |
| sNII | 2.33x |
| Individual | 2.19x |
| Total | 1.83x |
Important Date
| Event | Date |
|---|
| IPO Open | Wed, Jan 28, 2026 |
| IPO Close | Fri, Jan 30, 2026 |
| Allotment | Mon, Feb 2, 2026 |
| Refund | Tue, Feb 3, 2026 |
| Credit of Shares | Tue, Feb 3, 2026 |
| Listing | Wed, Feb 4, 2026 |
Day Wise Gmp
| Date | Price | GMP | Sub | Est Price | Profit | Updated |
|---|
| 03-02-2026 | ₹129.00 | ₹0.00 — | 1.83 | ₹129.00 | ₹0.00 | 00:16 |
| 01-02-2026 | ₹129.00 | ₹0.00 — | 1.83 | ₹129.00 | ₹0.00 | 23:55 |
| 31-01-2026 | ₹129.00 | ₹0.00 — | 1.83 | ₹129.00 | ₹0.00 | 23:58 |
| 30-01-2026 | ₹129.00 | ₹0.00 — | 1.83 | ₹129.00 | ₹0.00 | 23:58 |
| 29-01-2026 | ₹129.00 | ₹0.00 — | 0.20 | ₹129.00 | ₹0.00 | 00:00 |
| 28-01-2026 | ₹129.00 | ₹0.00 — | 0.00 | ₹129.00 | ₹0.00 | 00:07 |
| 26-01-2026 | ₹129.00 | ₹0.00 — | 0.00 | ₹129.00 | ₹0.00 | 08:39 |
Day Wise Subscribe
| Date | Anchor | QIB | NII | BNII | SNII | Total |
| 31 Jan | 1x | 1.01x | 2.08x | 1.95x | 2.33x | 1.83x |
| 30 Jan | 1x | 1.01x | 2.08x | 1.95x | 2.33x | 1.83x |
| 29 Jan | 1x | 0.99x | 0.64x | 0.48x | 0.98x | 0.64x |
Ipo Lot Size
| Application | Lots | Shares | Amount (₹) |
| Retail (Min) | 2 | 2,000 | 2,58,000 |
| Retail (Max) | 2 | 2,000 | 2,58,000 |
| S-HNI (Min) | 3 | 3,000 | 3,87,000 |
| S-HNI (Max) | 7 | 7,000 | 9,03,000 |
| B-HNI (Min) | 8 | 8,000 | 10,32,000 |
Ipo Reservation
| Category | Shares | Percentage |
|---|
| Market Maker Shares | 96,000 | 5.00% |
| QIB Shares | 9,08,000 | 47.29% |
| Anchor Investor Shares | 5,46,000 | 28.44% |
| QIB (Ex Anchor) | 3,62,000 | 18.85% |
| NII (HNI) | 2,76,000 | 14.37% |
| bNII > ₹10L | 1,84,000 | 9.58% |
| sNII < ₹10L | 92,000 | 4.79% |
| Retail | 6,40,000 | 33.33% |
| Total Shares | 19,20,000 | 100% |
About Company
tr> | Particulars | Details | | Dosage Forms | Products in various dosage forms including tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels. |
| Business Model | Operates as a Contract Development and Manufacturing Organization (CDMO), serving domestic and international markets such as Sri Lanka, Singapore, and the USA. |
| Product Focus | Combines classical Ayurvedic principles with modern nutraceutical science for liver care, women’s health, bone & joint health, cognitive support, and respiratory wellness. |
| Manufacturing Facility | Manufacturing facility in Gujarat covering approx. 10,763 sq. ft., equipped with modern infrastructure including 13 air handling units, separate processing areas, and quality control systems. |
| Certifications | GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, Halal certified, and FSSAI licensed. |
Objective of Ipo
| # | Issue Objects | Estimated Amount (₹ Cr.) |
| 1 | Purchase of Machineries for Automation in existing Manufacturing Unit | 4.22 |
| 2 | Purchase of Machineries for New Manufacturing Setup | 8.03 |
| 3 | Funding working capital requirements of the company | 5.50 |
| 4 | General Corporate Purposes | — |
Financial Report
| Metric | Value |
|---|
| ROE | 68.54% |
| ROCE | 49.09% |
| Debt / Equity | 0.54 |
| RoNW | 56.50% |
| PAT Margin | 16.59% |
| EBITDA Margin | 23.36% |
| Price to Book Value | 7.71 |
